SCHEDULE 13G/A: Schonfeld Strategic Advisors Reports 0.82% Stake in Fate Therapeutics

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, disclosing a 0.82% beneficial ownership stake in Fate Therapeutics, Inc. as of June 30, 2025.

Summary

• Schonfeld Strategic Advisors LLC reported beneficial ownership of 937,521 shares of Fate Therapeutics, Inc. common stock.
• This represents 0.82% of the total outstanding common stock of Fate Therapeutics, Inc.
• The percentage is based on 114,633,022 shares outstanding as of May 6, 2025, as reported in Fate Therapeutics' Form 10-Q filed on May 13, 2025.
• Schonfeld Strategic Advisors LLC holds sole voting and dispositive power over all 937,521 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. It's a routine disclosure of a passive investment by an institutional investor, which can be seen as a vote of confidence, albeit a small one. There are no negative implications within the filing itself.

Positives

• A significant institutional investor, Schonfeld Strategic Advisors LLC, maintains a position in Fate Therapeutics, indicating continued interest.
• The filing explicitly states the shares were acquired and are held in the ordinary course of business, not for control purposes, suggesting a passive investment.

Negatives

• The reported stake of 0.82% is below the 5% threshold, meaning Schonfeld is not a major shareholder influencing company decisions.

Future Outlook

NA

Management Comments

• Schonfeld Strategic Advisors LLC declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934 or any other purpose, the beneficial owner of any securities covered by this statement.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment adviser. It does not provide specific insights into broader industry trends for biotechnology or the competitive landscape for Fate Therapeutics, Inc. It merely reflects an institutional investor's position.

Related Party Transactions

• The securities are held by Schonfeld Strategic Advisors LLC as an investment adviser to several private funds and through third-party sub-advisers managing Schonfeld SMAs.
• The actual record and direct beneficial owners are clients of Schonfeld, who have the right to receive dividends or proceeds from the sale of such securities.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, confirming a passive stake by Schonfeld Strategic Advisors LLC.
• Management: No direct impact on management or strategic direction as the stake is passive and below control thresholds.

Next Steps

• Fate Therapeutics, Inc. will continue its operations and report financial results as per SEC requirements.
• Schonfeld Strategic Advisors LLC will continue to manage its investment in Fate Therapeutics, Inc. and file further amendments to its Schedule 13G if its beneficial ownership changes significantly (e.g., crosses 5% or drops below reporting thresholds).

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive, sub-1% ownership stake by an institutional investor. It provides no new fundamental information about Fate Therapeutics, Inc.'s operations, financial performance, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on prior analysis of the company's fundamentals rather than this ownership update.

Keywords

Fate Therapeutics, Schonfeld Strategic Advisors, FTTE, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Investment Adviser